相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Epidemiology of extended-spectrum β-lactamase and metallo-β-lactamase-producing Escherichia coli in South Asia
Kamrul Islam et al.
FUTURE MICROBIOLOGY (2021)
ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007-18
James A. Karlowsky et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study
A. Henderson et al.
CLINICAL INFECTIOUS DISEASES (2021)
Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study
Zafer Tandogdu et al.
WORLD JOURNAL OF UROLOGY (2020)
Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically III Patients
Rajbharan Yadav et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
β-lactam antibiotic versus combined β-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis
Aaron James Heffernan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?
Sima L. Sharara et al.
CLINICAL INFECTIOUS DISEASES (2020)
Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model
Thomas P. Lodise et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model
Aaron J. Heffernan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis
C. Fleischmann-Struzek et al.
INTENSIVE CARE MEDICINE (2020)
Combination Therapy with Aminoglycoside in Bacteremiasdue to ESBL-Producing Enterobacteriaceae in ICU
Lucie Benetazzo et al.
ANTIBIOTICS-BASEL (2020)
Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
Jianguo Li et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options
Gisele Peirano et al.
DRUGS (2019)
OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27
Patrick N. A. Harris et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa
Marguerite L. Monogue et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling
Rajbharan Yadav et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli
Lisa M. Schechter et al.
MBIO (2018)
Comparative transcriptomics of multidrug-resistant Acinetobacter baumannii in response to antibiotic treatments
Hao Qin et al.
SCIENTIFIC REPORTS (2018)
The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model
G. L. Drusano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Multicopy plasmids potentiate the evolution of antibiotic resistance in bacteria
Alvaro San Milian et al.
NATURE ECOLOGY & EVOLUTION (2017)
Amikacin: Uses, Resistance, and Prospects for Inhibition
Maria S. Ramirez et al.
MOLECULES (2017)
Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling
Rajbharan Yadav et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically III Patients
Abdulaziz S. Alobaid et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients
Francesca Mattioli et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Mervyn Singer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes
Tawanda Gumbo et al.
CLINICAL INFECTIOUS DISEASES (2015)
Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study
E. Esteve-Palau et al.
JOURNAL OF INFECTION (2015)
Urosepsis: Overview of the Diagnostic and Treatment Challenges
Florian M. E. Wagenlehner et al.
MICROBIOLOGY SPECTRUM (2015)
Molecular Characterization of Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae in the Countries of the Gulf Cooperation Council: Dominance of OXA-48 and NDM Producers
Hosam M. Zowawi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Interaction of Drug- and Granulocyte-Mediated Killing of Pseudomonas aeruginosa in a Murine Pneumonia Model
George Louis Drusano et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
Jason A. Roberts et al.
LANCET INFECTIOUS DISEASES (2014)
An alternate pathophysiologic paradigm of sepsis and septic shock Implications for optimizing antimicrobial therapy
Anand Kumar
VIRULENCE (2014)
Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases
Arnold Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
Jared L. Crandon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study
Mitchell M. Levy et al.
LANCET INFECTIOUS DISEASES (2012)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
A Robicsek et al.
NATURE MEDICINE (2006)
分享论文
